Novel treatments for hemophilia through rebalancing of the coagulation cascade

Authors: Zhao, Y; Weyand, AC.; Shavit, JA.

Affiliations: Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA.

Publication: Pediatric Blood & Cancer; 2021. e28934 ; March 2021

Abstract: Hemophilia A and B are inherited hemorrhagic disorders that result from alterations in the coagulation cascade. Aside from spontaneous bleeding, the main complication of hemophilia is hemarthrosis. Progress over the last three decades, specifically prophylaxis using recombinant factor, has prevented hemarthrosis and lengthened patient life expectancies. However, many treatments require frequent dosing up to three times a week, and alloantibodies (inhibitors) against replacement factor continues to be an issue. These problems call for novel treatments for patients with hemophilia. Although there has been progress in extended half-life factors and mimetics of factor VIII, an alternative treatment methodology is to rebalance the activities of pro- and anticoagulant factors through inhibition of the natural anticoagulants: antithrombin, tissue factor pathway inhibitor, protein C, and protein S. This review will explore the efficacy of targeting these inhibitory pathways from preclinical development through clinical trials and delve into concerns of thrombotic risk.